Amgen shares top $100 as fears fade over biosimilars | Pacific Coast Business Times

Montecito

Tolman Wiker

Pac Premier

Fielding

American Riviera

Loading...

You are here: Home > Banking & Finance > Current Article

Amgen shares top $100 as fears fade over biosimilars

By Stephen Nellis / Friday, April 5th, 2013 / Comments Off on Amgen shares top $100 as fears fade over biosimilars

This article is only available to Business Times subscribers

Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
Check the STATUS of your Subscription Account.

NEXT ARTICLE →
Up in the air: When it makes sense to take your small business into the cloud

← PREVIOUS ARTICLE
Green Coast 2013: How the region is leading the way in energy efficiency

About the author

Stephen Nellis

Senior editor

View all articles by Stephen Nellis »

Related Articles

Friday, August 16th, 2019

Amgen fends off biosimilar for arthritis drug Enbrel

Friday, August 9th, 2019

Judge blocks sale of competitor for Amgen’s Enbrel

Thursday, August 8th, 2019

MannKind triples second quarter revenues

You might also like...

MindBody acquiring India-based Simplicity First